Pacific Biosciences of California (PACB)

Currency in USD
1.350
+0.090(+7.14%)
Closed·
After Hours
1.3500.000(0.00%)
·
PACB Scorecard
Full Analysis
May have trouble making interest payments on debt
PACB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.2911.510
52 wk Range
0.8512.720
Key Statistics
Prev. Close
1.26
Open
1.45
Day's Range
1.291-1.51
52 wk Range
0.851-2.72
Volume
9.94M
Average Volume (3m)
9.26M
1-Year Change
-17.65%
Book Value / Share
0.31
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PACB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.055
Upside
+52.22%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Pacific Biosciences of California SWOT Analysis


Genomics Headwinds
PacBio faces challenges in the genomics industry, with revised guidance reflecting slower sales cycles and macroeconomic pressures on its Revio system placements
Financial Resilience
Explore PacBio's ambitious $75 million cost-out run-rate target and its goal to achieve free cash flow positivity by 2026, showcasing strategic financial management
Market Dynamics
Delve into the complex interplay of macroeconomic factors, capital expenditure trends, and PacBio's innovative commercial strategies in the evolving genomics secto
Analyst Perspectives
Barclays Capital Inc. sets price targets ranging from $2.00 to $3.00, reflecting cautious optimism amidst PacBio's efforts to navigate market challenges
Read full SWOT analysis

Pacific Biosciences of California Earnings Call Summary for Q2/2025

  • Pacific Biosciences reported Q2 2025 revenue of $39.8M, beating expectations by 8.57%, with EPS loss of $0.13 outperforming forecasts
  • Stock surged 10.32% in premarket trading after initial 8.7% drop, reflecting investor optimism despite volatility
  • Company maintained full-year revenue guidance of $155M-$165M, targeting 40%+ gross margin by year-end and positive cash flow by 2027
  • International growth strong, particularly in APAC and EMEA; new products launched including Spark Chemistry and Vega platform
  • Challenges include NIH funding uncertainty, declining instrument revenue, and competition from short-read sequencing technologies
Last Updated: 08/08/2025, 12:28
Read Full Transcript

Compare PACB to Peers and Sector

Metrics to compare
PACB
Peers
Sector
Relationship
P/E Ratio
−0.6x−0.1x−0.5x
PEG Ratio
0.010.070.00
Price/Book
4.1x1.9x2.6x
Price / LTM Sales
2.5x1.9x3.3x
Upside (Analyst Target)
42.9%22.3%43.4%
Fair Value Upside
Unlock19.8%7.1%Unlock

Analyst Ratings

6 Buy
7 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 2.055
(+52.22% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-0.13 / -0.17
Revenue / Forecast
39.80M / 36.66M
EPS Revisions
Last 90 days

PACB Income Statement

People Also Watch

46.630
ASTS
-2.26%
159.03
CRCL
+3.99%
60.87
TEM
+3.63%

FAQ

What Stock Exchange Does Pacific Biosciences Trade On?

Pacific Biosciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Pacific Biosciences?

The stock symbol for Pacific Biosciences is "PACB."

What Is the Pacific Biosciences Market Cap?

As of today, Pacific Biosciences market cap is 399.11M.

What Is Pacific Biosciences's Earnings Per Share (TTM)?

The Pacific Biosciences EPS (TTM) is -2.34.

When Is the Next Pacific Biosciences Earnings Date?

Pacific Biosciences will release its next earnings report on 09 Nov 2025.

From a Technical Analysis Perspective, Is PACB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Pacific Biosciences Stock Split?

Pacific Biosciences has split 0 times.

How Many Employees Does Pacific Biosciences Have?

Pacific Biosciences has 575 employees.

What is the current trading status of Pacific Biosciences (PACB)?

As of 08 Aug 2025, Pacific Biosciences (PACB) is trading at a price of 1.35, with a previous close of 1.26. The stock has fluctuated within a day range of 1.29 to 1.51, while its 52-week range spans from 0.85 to 2.72.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.